NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Xenopat

Xenopat

Private
BarcelonaHealthcare & Life Scienceshttp://xenopat.com/

Last Round

Grant

Apr 27, 2025

Total Funding Raised

$245,000

Company Overview

Xenopat is a biotechnology company that provides R&D services based on orthoxenografts®, which are mouse models with implanted human tumors, for anticancer drug development and personalized cancer treatment.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Clinical Trials, Precision Medicine, Biotechnology

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

preclinical CROpatient-derived xenograftPDX modelorthotopic xenograftoncology research servicesin vivo modelspersonalized oncologycancer drug testingmouse avatartumor avatarpreclinical animal modelstumor biobankdrug discovery servicesCROchemosensitivity testingfee-for-service research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Xenopat Comparables

Compare Xenopat with similar companies based on industry and business-model similarity.

Xenopat comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
XenTech SAS
87%
Experimental Pharmacology & Oncology Berlin-Buch GmbH
82%
Pharmatest Services
77%

Xenopat Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantApr 27, 2025
GrantFeb 22, 2018

Key People

Founding team and executive leadership

Anna Portela Mestres

CEO & Co-founder

Founding Team

Xenopat Investors

Notable investors and investment history

Xenopat investors
InvestorRounds
ACCIÓ - Agency for Business CompetitivenessGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 12, 2025

    Monthly visitors grew 134% MoM.

  • Feb 22, 2018

    $93K grant received from ACCIÓ.

Xenopat Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Xenopat Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Xenopat's valuation, stock price, and market status.

Firmographic Details

HeadquartersBarcelona
Employee Range7
Year Founded2014
Last FundingApr 27, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.